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The evolution and progression of multiple myeloma and its precursors over time is poorly
understood. Here, we investigate the landscape and timing of mutational processes shaping
multiple myeloma evolution in a large cohort of 89 whole genomes and 973 exomes. We
identify eight processes, including a mutational signature caused by exposure to melphalan.
Reconstructing the chronological activity of each mutational signature, we estimate that the
initial transformation of a germinal center B-cell usually occurred during the first 2nd-3rd
decades of life. We define four main patterns of activation-induced deaminase (AID) and
apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) mutagenesis over time,
including a subset of patients with evidence of prolonged AID activity during the pre-
malignant phase, indicating antigen-responsiveness and germinal center reentry. Our findings
provide a framework to study the etiology of multiple myeloma and explore strategies for
prevention and early detection.
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Cancers are usually preceded by asymptomatic clonal enti-ties that may be detected several years before progressionto overt malignancy1,2. This suggests a long evolutionary
process where genomic driver events accumulate over time,
conferring advantage to distinct subclones, allowing their
expansion and progression3. Understanding the timeline of pre-
malignant clonal initiation and progression is vital to develop
strategies for early cancer diagnosis and prevention. Intriguingly,
recent reports have shown how different cancer types acquire the
first driver event approximately 20–40 years before diagnosis,
often when the individual is aged between 20 and 30 years2,4,5.
Such studies have been made possible by the existence of muta-
tional processes whose activity is constant over time (i.e., clock-
like), producing a mutational burden proportional to the cancer
cell age4,6–9.
Multiple myeloma (MM) is always preceded by an asympto-
matic expansion of clonal plasma cells, clinically recognized as
monoclonal gammopathy of undetermined significance (MGUS)
or smoldering myeloma (SMM)10,11,12. Historically, transloca-
tions between the IGH locus and recurrent oncogenes and tri-
somies of odd chromosomes (i.e., hyperdiploidy) have been
considered as initiating events13,14. Hyperdiploidy is detectable in
>60% of MM patients and has been thought to result from a
single catastrophic mitosis13. In a recent whole-genome sequen-
cing (WGS) study, we provided evidence that hyperdiploid
cytogenetic profiles often reflect the sum of multiple gains
acquired in different time windows15. This observation was based
on the corrected ratio of duplicated and non-duplicated clonal
point mutations within large chromosomal gains (i.e., molecular
time)2,15,16. While this allowed us to re-construct the relative
order in which events occurred, translating these estimates into
an absolute time scale was not possible, because, in contrast to
some solid cancers5, MM does not show a reliable relationship
between global mutation burden and patient age6,17.
Here we characterize the landscape and temporal activity of
mutational processes involved in MM pathogenesis, to recon-
struct the evolutionary history in absolute time, and finally esti-
mate the patient age at disease initiation.
Results
The MM mutational signature landscape. To comprehensively
assess the catalog of mutational processes involved in MM
pathogenesis, we interrogated WGS data from 52 patients (Sup-
plementary Data 1). Twenty-six patients (50%) had >1 sample
collected at different time points for a total of 89 tumor samples
(Supplementary Table 1). To improve the accuracy of de novo
mutational signatures extraction, we integrated two independent
approaches: SigProfiler and the hierarchical Dirichlet process
(hdp; “Methods”)9,18. Eight single-base substitution (SBS) sig-
natures were identified, seven of which were compatible with one
included in the most recent mutational signature catalog: SBS1,
SBS2, SBS5, SBS8, SBS9, SBS13, and SBS18 (Fig. 1a; https://
cancer.sanger.ac.uk/cosmic/signatures/SBS/)9. The final muta-
tional signature, here named SBS-MM1, did not correspond to
any of the COSMIC reference mutational signatures but was
compatible with a recently reported MM mutational signature of
unknown etiology (Fig. 1a and Supplementary Fig. 1A, B)9,17–19.
The existence of SBS-MM1 as a distinct mutational process was
further validated by extending the mutational signature analysis
to include the two flanking bases 5’ and 3’ to the mutated base
(1536 classes or 5-nucleotide context; Supplementary Fig. 1C, D).
Despite their statistical robustness, in heterogeneous cancer
types such as MM, de novo extraction algorithms can be biased
by the bleeding of mutational signatures between samples, where
mutational signatures present in only part of the dataset are
erroneously assigned to every sample17,18. To avoid this effect and
accurately estimate the contribution of each mutational signature,
we designed an algorithm—named mmsig—where the eight
extracted mutational signatures in MM were fitted for each
patient. The contribution of each mutational signature was
corrected based on the cosine similarity between the original 96-
class mutational profile and the reconstructed profile generated
without that mutational signature (“Methods”). mmsig revealed
SBS-MM1 activity only in samples obtained at relapse, from 9
patients (17%) (Fig. 1b, c and Supplementary Data 2). Interest-
ingly, this mutational process was particularly enriched after
exposure to high-dose melphalan and autologous stem cell
transplantation (5/9 posttransplant vs. 1/29 relapsed after other
therapies; Fisher’s test p= 0.001). The only non-transplanted
patient with evidence of SBS-MM1 activity (PD26414) had
received several treatment lines, including melphalan, and
cyclophosphamide for stem cell mobilization before the first
sample collection. In contrast, SBS-MM1 was absent in all
pre-treatment samples (i.e., SMM and newly diagnosed MM)
(0/20 vs. 5/9; p= 0.001, Fisher’s exact test). To further investigate
association between treatment and SBS-MM1, we analyzed exome
data from two independent validation cohorts: (1) 72 patients
with paired samples collected at diagnosis and relapse, with 70%
cases exposed to alkylating agents (CoMMpass trial); and (2) 40
MM patients all previously exposed to alkylating agents and
refractory to both bortezomib and lenalidomide (Fig. 1d)20,21. In
line with our observations, SBS-MM1 was not present in therapy-
naive samples but was detected in the same patients at relapse and
in the independent relapsed/refractory cohort. No clinical or
recurrent genomic features were significantly associated with
SBS-MM1, except prior exposure to melphalan (Supplementary
Table 2).
Several therapy-related mutational signatures (e.g., platinum-
SBS31/SBS35, azathioprine-SBS32, and SBS25) have been asso-
ciated with transcriptional strand bias, reflecting transcription-
coupled nucleotide excision repair activity on damaged DNA9.
Similarly, SBS-MM1 showed a strong transcriptional strand bias
in C>T, involving distinct trinucleotide (e.g., C[C>T]A, G[C>T]
A, G[C>T]C, G[C>T]G, G[C>T]T) and five-nucleotide contexts
(e.g., GG[C>T]AA, GG[C>T]AC, GG[C>T]AG, GG[C>T]CA,
GG[C>T]TA, GG[C>T]TG), supporting the association between
this mutational signature and chemotherapy-induced DNA
damage (Fig. 1e and Supplementary Data 2–4).
A recent study investigated the mutagenic impact of 79 known
or suspected environmental carcinogens on human-induced
pluripotent stem cells in vitro22. Melphalan exposure was tested
in this study; however, they excluded this experiment from
further analysis due to a signal-to-noise-ratio <222. Re-analyzing
their published data by two independent de novo mutational sig-
nature extraction algorithms (hdp and SigProfiler), we identified a
significant SBS-MM1 contribution in the melphalan-exposed cells
(i.e., MSM0.10) but not in 15 control cell lines or 89 patients with
chronic lymphocytic leukemia (CLL) (Supplementary Fig. 2).
These negative controls were included in the de novo extraction
to correct for the potential inter-bleeding of mutational signatures
across different samples18. As a further confirmation, the 96-class
mutational profile of MSM0.10 was best explained by the
combination of SBS-MM1 and the “control” mutational signa-
ture, a signature detected in single-cell expansions irrespective of
exposures and attributed to the experimental conditions (Supple-
mentary Data 5 and 6). Finally, these results were confirmed by
mutational signature fitting with mmsig (Supplementary Figs. 3
and 4).
Overall, these data suggest the existence of a distinct mutational
signature associated with melphalan exposure, demonstrating that
standard chemotherapy can alter the tumor genome in MM.
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Whether this contributes to the phenotype at relapse and
subsequent evolutionary trajectory remains to be addressed.
Investigating the topography of mutational signatures involved
in MM pathogenesis, we observed a strong enrichment of SBS9,
SBS8, and SBS5 in late-replicating regions with low chromatin
accessibility, in line with observations from other cancers
(Supplementary Fig. 5)23. Similar patterns of enrichment were
found for SBS-MM1.
Two clock-like processes (SBS1 and SBS5) were observed in all
patients, in line with previous works (Fig. 1c, d)6,7,9,17,24–26.
APOBEC (SBS2 and SBS13) was also confirmed as an essential
mutational process, absent in only 9 patients (17%)17,25,27,28.
While SBS2 was always the most common APOBEC signature
(43/52; 83%), SBS13 activity was observed in 6 cases (11.5%)
(Supplementary Data 2). Two of these were characterized by high
mutation burden and >20% contribution from APOBEC (SBS2
+SBS13). Both patients had IGH translocations involving MAFB
and MAFA, confirming the known association between these
IGH translocations and high APOBEC mutational activity
(Supplementary Data 1)26,27. Interestingly, these two cases were
the only ones without detectable non-canonical activation-
induced deaminase (AID) (SBS9) activity.
APOBEC mutational activity in cancer can be sustained by two
main isoforms: APOBEC3A and APOBEC3B. The contribution of
each isoform can be estimated by considering the second base 5’ to
the mutated cytosine (4-nucleotide context)29. In solid cancers,
APOBEC3A has been suggested as the most active isoform9. In
contrast, we found a 1:1 ratio in all MM patients, with the notable
exception ofMAFB/MAFA translocated cases, where the ratio was
higher (Fig. 2a). The association between MAF translocations and
increased APOBEC3A activity over APOBEC3B was further
confirmed in exome data from 692 newly diagnosed MMs with
available IGH translocation data (Fig. 2b, c). Therefore, we asked
whether variations in APOBEC3A/3B ratio in solid cancers could
be similarly explained by the total APOBEC mutation burden.
Analyzing the 4-nucleotide context of 788 WGSs from 27 tumor
types with evidence of APOBEC activity enrolled within the
PCAWG ICGC consortium, we observed a strong positive
association between APOBEC3A/APOBEC3B ratio and APOBEC
mutational burden (linear regression p < 0.0001; Fig. 2d, e).
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Fig. 1 Multiple myeloma mutational signature landscape. a The 8 mutational signatures extracted from 89 WGSs from 52 MM patients. b, c The relative
(b) and absolute (c) contribution of each mutational signature for each patient. The x-axis labels are colored according to disease stage and treatment
history: red= treatment naive; blue= relapsed cases without a full clinical annotation; black= relapsed cases after transplant with high-dose melphalan;
purple= relapsed cases never exposed to transplant with high-dose melphalan; gray=missing clinical data. d Relative contribution of all eight
MM mutational signatures on exome data collected at diagnosis (ND= newly diagnosed), relapsed, and when the disease was refractory to both
bortezomib and lenalidomide (i.e., double-ref). e Transcriptional strand bias profile of patients with (top) and without (bottom) evidence of SBS-MM1.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15740-9 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1917 | https://doi.org/10.1038/s41467-020-15740-9 |www.nature.com/naturecommunications 3
Conversely, the APOBEC 3A/3B ratio was closer to 1:1 when the
global APOBEC mutation rate was low. Overall, this suggests
the existence of two different APOBEC mutational patterns at the
whole-genome level: one where a few hundreds of mutations are
caused by both APOBEC3A and APOBEC3B and another where
the APOBEC mutational burden is higher and mainly sustained
by APOBEC3A. Tumors with high APOBEC activity showed
similar patterns across MM and solid tumors, indicating a
potential common mechanism.
Kataegis and localized mutational events in MM. Canonical
and non-canonical AID activity (c-AID—SBS84 and nc-AID—
SBS9, respectively) has been described in kataegis regions from
immunoglobulin loci in MM and other post-germinal center
lymphoproliferative disorders9,17,24,30,31. c-AID activity was not
extracted genome-wide by SigProfiler or hdp, consistent with its
localized mutational activity on specific hotspots such as
the immunoglobulin loci (Supplementary Fig. 6)18. Here both
processes act in clusters of mutations, reflecting one of the
most important germinal center (GC) processes: somatic
hypermutation (SHM)32. Outside of the immunoglobulin loci,
127 kataegis events were extracted (median 2 per patient; range
0–13), mostly induced by nc-AID or APOBEC (Fig. 3a–d).
Forty-seven non-immunoglobulin kataegis (37%) were located
<1 Mb from at least one structural variant (SV) breakpoint.
Interestingly, 95% of these events were caused by APOBEC
(Fig. 3c–e). In contrast, nc-AID kataegis events were usually not
associated with SVs (Fig. 3d–f). Overall, this suggests two main
routes of acquisition of kataegis outside of the immunoglobulin
loci in MM: one caused by AID activity, likely reflecting GC
exposure; and another caused by APOBEC, usually co-occurring
with structural chromosomal changes.
Temporal patterns of MMmutational signatures. To investigate
the activity over time of each mutational process, we recon-
structed the phylogenetic tree for each patient with more than
one sample collected at different time points (n= 26) and sub-
divided all mutations into three main categories15,17: (1) early
clonal (i.e., mutations identified as clonal in all samples); (2) late
clonal (i.e., clonal in at least one sample but not in all); and (3)
subclonal (not clonal in any sample) (Fig. 4a). nc-AID was
strongly enriched among early clonal mutations compared to late
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clonal and subclonal (p < 0.0001; pairwise Wilcoxon test). In 18
cases (69%), nc-AID was exclusively detected among early clonal
mutations. Interestingly, a persistent nc-AID contribution was
still observed among late clonal and subclonal mutations in 8
(31%) patients, suggesting GC exposure and AID-driven sub-
clonal diversification after the most recent common ancestor
(MRCA) (Fig. 4a).
We went on to look for additional evidence of AID activity
after the MRCA, either for a limited period of time or ongoing at
the time of MM diagnosis. First, we searched for the mutational
footprint of c-AID activity in the IGH locus. In 26 paired WGS
samples, we identified 196 unique mutations that were not shared
across all samples from the same patient, showing clear evidence
of c-AID contribution (Supplementary Fig. 7A). These results
were confirmed in sequential samples from 72 patients in
CoMMpass study by whole-exome sequencing (Supplementary
Fig. 7B, C). Next, we reconstructed the third complementarity
determining region (CDR3) of IGH from WGS data in the same
26 paired samples (Supplementary Table 3). Interestingly, the
CDR3 sequences were identical across sample pairs in all patients.
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Fig. 3 Kataegis in multiple myeloma. a The distribution of all kataegis events extracted across 52 MM patients, each color reflecting a distinct patient.
b Number of kataegis events per patient. c In kataegis events close to at least one SV breakpoint, APOBEC (SBS2 and SBS13) was the main mutational
process. d Other kataegis events not associated with any SV breakpoints were dominated by nc-AID. e Example of APOBEC-mediated kataegis associated
with chromothripsis. f Example of nc-AID kateagis not associated with SV. In e, f, black dots represent the chromosome ploidy status. Vertical black, blue,
green, and red lines reflect translocations, inversions, tandem duplications, and deletion, respectively. Below each copy number/structural variant plot, we
reported the inter-mutational distance of all SNVs, color-coded by class (blue: C>A, black C>G, red C>T, gray T>A, green T>C, pink T>G).
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Highly conserved CDR3 sequences over time in MM is consistent
with previous studies33, including CDR3 reconstruction from
RNA sequencing of sequential samples in the CoMMpass
cohort34.
To determine whether AID mutational activity is still ongoing
at the time of MM diagnosis, we analyzed expression of the
AICDA gene (encoding AID). There was no evidence of AICDA
expression in bulk RNA sequencing (n= 792 in the CoMMpass
study; Supplementary Fig. 7D) or at the single-cell level (Fig. 4b),
consistent with previous reports that AID protein is not
expressed in MM cells35. Furthermore, single-cell analysis of
immunoglobulin CDR3 sequences revealed no intra-clonal
variation36. Taken together, these observations suggest that AID
mutational activity persists for some time after disease initiation,
driving late clonal and subclonal mutagenesis in a subset of
patients, but is no longer active at the time of MM diagnosis. We
hypothesize that myeloma precursor cells may be antigen
responsive, leading to repeated cycles of GC re-entry until the
disease becomes antigen and GC independent.
SBS-MM1 and its characteristic pattern of transcriptional
strand bias were detected only among late clonal and subclonal
mutations in patients exposed to melphalan, consistent with an
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association with treatment (Fig. 4c and Supplementary Fig. 8).
Patient PD26403 was an emblematic example of the changing
mutational signature landscape over time in relation to disease
progression and treatment (Supplementary Fig. 9). This patient
was the only one with samples collected during the smoldering
phase, at the time of progression into symptomatic MM, and at
first relapse after therapy with high-dose melphalan. Both
progressions were characterized by a branching evolution, but
SBS-MM1 was only detected in mutations selected after therapy,
not after spontaneous progression from SMM to MM. To further
investigate the association between melphalan exposure and SBS-
MM1, we analyzed the mutational signature landscape of 24
patients enrolled in the CoMMpass trial with whole exome and
low-coverage WGS performed at baseline and the first relapse
(Supplementary Data 7). Reconstructing the phylogenetic tree of
each patient, we divided mutations into four main groups: clonal
(i.e., trunk of the phylogenetic tree) and those following one of
the three selection patterns from diagnosis to relapse: negative,
positive, and neutral (i.e., unchanged cancer cell fraction)
(“Methods”). Each group was further separated by exposure to
high-dose melphalan. In line with its therapy-related etiology,
SBS-MM1 was identified only among mutations positively
selected after melphalan exposure (Fig. 4d).
In contrast to AID, APOBEC was significantly enriched among
late clonal and subclonal mutations (p < 0.0001; pairwise
Wilcoxon test), with 8 patients (31%) having no detectable
APOBEC among early clonal variants (Fig. 4a). The increasing
activity of APOBECs during late phases of cancer development
was also confirmed in the CoMMpass exome cohort (Fig. 4e, f;
p < 0.001 Wilcoxon test). Interestingly, in this large exome series,
SBS2 and SBS13 were particularly enriched among nonsynon-
ymous compared to non-coding mutations (21.3% vs. 11.6%;
Fisher’s test p < 0.001), confirming the role of APOBECs in MM
progression and subclonal diversification (Fig. 4g)37. SBS8 and
SBS18 were detected in 45 (86%) and 6 (11%) cases, respectively,
usually with higher contribution among late clonal and subclonal
mutations.
The early clonal clusters usually accounted for >50% of the
total mutation burden (median 70.6%; range 33–100%), and its
composition reflects the sum of different mutational processes
active during different time windows in the preclinical phase. To
investigate the temporal activity of each mutational process
among early clonal mutations, we took advantage of primary and
secondary chromosomal gains in 33 patients where early clonal
mutations could be divided into duplicated mutations (i.e.,
present on two alleles and therefore acquired before the
duplication) or non-duplicated mutations (i.e., detected on a
single allele), reflecting either pre and post-gain mutations on the
minor allele or post-gain mutations acquired on one of the
duplicated alleles (“Methods”)15. While SBS1 and SBS5 were
active in both groups of mutations (pre- and post-gain), nc-AID
(SBS9) was significantly enriched in the pre-gain mutations (p <
0.0001), highlighting its involvement in the earliest phase of MM
pathogenesis (Fig. 5a, b). Mutations attributed to nc-AID were
also detected on one single allele. This can be explained by either
persistent AID activity causing mutations after the duplication or
mutations acquired before the gain on the minor allele. To resolve
this ambiguity, we restricted our analysis to large areas of copy
neutral loss of heterozygosity (LOH) in 16 patients, where the
minor allele was lost and the major duplicated. In these cases, all
mutations present on a single allele must be acquired after the
gain. While nc-AID activity was more predominant before the
LOH event, it could still be detected after (Fig. 5c). Similarly, we
characterized mutations acquired between two independent gains
of the same allele (i.e., tetrasomy). Sixteen clonal tetrasomies were
observed in 10 patients. Using our molecular time approach, we
estimated that six patients had one or more tetrasomy acquired in
two distinct time windows2,15. In three of these, nc-AID was
identified between the two duplications (i.e., mutations on two
alleles out of four) (Fig. 5d). Notably, out of the 12 patients
without subclonal nc-AID mutations, 2 patients with paired
samples showed evidence of prolonged nc-AID activity after the
first gain. Overall, these data further support the notion that AID
mutational activity is not confined to the initial GC contact when
transformation occurs but in most cases continues to shape the
genome across a considerable time span.
Interestingly, APOBEC activity was generally low (n= 8) or
absent (n= 20) before chromosomal gains except for the two
MAFA/MAFB MM patients. Here APOBEC was highly active
already in the earliest phases, and nc-AID was not detectable
at any stage. To investigate whether AID was active at all in
these two cases, we analyzed the mutational profiles of their
immunoglobulin loci. Despite the limited number of mutations, a
minimal c-AID activity was detected (Supplementary Fig. 10A).
To further confirm c-AID activity on the immunoglobulin loci in
MM patients with high APOBEC mutational burden, we
interrogated exome data from 70 and 863 newly diagnosed MM
patients with high and low APOBEC activity, respectively26. No
differences were observed between these two groups (Supple-
mentary Fig. 10B, C), confirming that all cases of MM have
undergone SHM.
Although SBS5 causes the majority of mutations during all
phases of tumor development, different temporal patterns of AID
and APOBEC mutagenesis may represent footprints of cellular
processes and exposures during the evolutionary trajectory
toward MM. Our data suggest at least four such patterns (Fig. 5e):
(1) where APOBEC plays a major role during all evolutionary
phases, including cancer initiation, and where AID contribution
is minimal; (2) where APOBEC is not involved in any phase; (3)
where AID is active only during the very early phase of cancer
initiation; and (4) where AID is the main mutational process
since the very first phases of cancer development and still plays a
role in the late subclonal diversification.
Clock-like mutational process in MM. Similar to other
cancers2,6,9, we found SBS1 and SBS5 to be active in all phases of
MM in all patients. In many cancers and normal tissues, these
mutational signatures are correlated with patient age4,6–8,38,39.
Previous results from a small cohort of MM exomes (n= 68)
showed a modest correlation for SBS1 but not for SBS56. Here we
employed several approaches to determine whether MM does
indeed have a clock-like mutational process, integrating our WGS
cohort with a large exome series.
First, we assessed the relationship between patient age and the
mutational burden attributed to each mutational signature at
diagnosis of MM in the CoMMpass exome dataset (n= 764)
using linear regression models. Significant relationships were
identified for SBS5 [slope 1.55 (95% confidence interval (CI)
0.97–2.14); p < 0.0001] and SBS1 [slope 0.29 (95% CI 0.13–0.45);
p= 0.0003], but none of the other mutational signatures (Fig. 6a
and Supplementary Data 8). Despite the strong correlation, there
was considerable variation in SBS1 and SBS5 mutational burden
between individual patients that could not be explained by age
alone. Next, we applied linear mixed-effects (LME) models to 72
patients in the CoMMpass dataset with paired diagnosis and
relapse exomes, allowing for each patient to accumulate
mutations at a different rate5. The LME model confirmed a
strong linear relationship between SBS5 and age (p < 0.0001) and
a weaker association for SBS1 (Fig. 6b and Supplementary
Data 8). Finally, to address the SBS5 mutation rate over time in
more detail, we applied similar LME models to our WGS cohort
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(the entire computational workflow is reported in Supplementary
Data 9). Here, thanks to the higher resolution of WGS data, we
were able to quantify the SBS5 mutational activity in each
subclone and define the major evolutionary trajectories (“Meth-
ods”)5. This is required because mutations are independently
acquired across distinct subclones. Collapsing all subclones
together would, therefore, overestimate the mutation rate. Again,
we observed that the SBS5 mutation burden increased linearly
with patient age, at an average rate of 38.8 mutations per year
across the cohort (95% CI 35.74–41.78), with a between-patient
standard deviation of 7.1. (Fig. 6c, Supplementary Fig. 11, and
Supplementary Data 9). The between-patient variation in our
study was similar in magnitude to that observed by Mitchell et al.
in kidney cancer using a similar approach, reporting an average
mutation rate of 89 per year, with a between-patient standard
deviation of 175.
Several factors may affect the power of WGS to identify
mutations in a tumor sample, such as the sequencing coverage,
tumor purity, and ploidy. If these factors confound the estimation
of SBS5 mutation burden, adjusting for them in an LME model
may provide a more accurate molecular clock. Furthermore, it is
possible that the SBS5 mutation rate accelerates during the late
phases of tumor evolution and subclonal diversification. We
tested for this effect by including a quadratic term for age in our
LME model, effectively allowing the mutation rate to paraboli-
cally increase with age5. Adjusting for the above features did not
improve LME model fit, and the estimated SBS5 mutation rate
remained largely unchanged (Supplementary Fig. 12, Supple-
mentary Data 9) Furthermore, the estimated SBS5 mutation rate
was independent from disease stage (i.e., SMM, newly diagnosed
MM, or relapsed MM; Bonferroni–Holm adjusted p= 1 by
pairwise Wilcoxon test; Supplementary Fig. 11, Supplementary
Data 9). Taken together, our data suggest that SBS5 mutations
accumulate at a constant rate in each MM tumor, similar to other
cancers and normal tissues4–7,38,39.
Considering the clock-like behavior of SBS5 in MM, we would
expect a similar pattern in other B cell-derived lymphoprolifera-
tive disorders. To confirm this, we interrogated 89 CLL and 107 B
cell lymphoma genomes included in the ICGC/PCAWG
consortium. The association between SBS5 mutational burden
and patient age was confirmed by linear regression analysis in
both non-hypermutated B cell lymphomas [slope 28.21 (standard
error 4.87); p < 0.0001] and CLL [slope 18.6 (standard error 4.8);
p= 0.0006] (Fig. 6d and “Methods”). Interestingly, mutated and
unmutated CLL showed a similar slope, suggesting that the
underlying biology is more important in determining the SBS5
mutation rate over time than subsequent environmental expo-
sures (e.g., antigen-driven selection in the GC).
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Timing the initiation and evolution of MM. Having established
SBS5 as a molecular clock in MM, we applied it to estimate the
absolute age of each patient when landmark events occurred
during tumor evolution2,4,5. This included primary and second-
ary chromosomal gains as well as emergence of the MRCA. Based
on the SBS5 mutation rate per year of each patient, we translated
the number of SBS5 mutations that had accumulated before each
landmark event into an estimated patient age when that event
occurred. MRCA timing was estimated based on early clonal
SBS5 mutation burden for patients with multiple samples avail-
able. The median time lag between the age at MRCA and at the
first sample collection varied greatly (14.2 years; range 0–45)
(Supplementary Fig. 13 and Supplementary Data 9). In some
patients, the estimated age when the MRCA emerged was very
close to the sample collection, which could also reflect an over-
estimation of clonal mutation burden. This may occur when a
branch of the tumor phylogenetic tree is inappropriately assigned
as the trunk because of missed spatial and genomic heterogeneity
and sampling bias40.
To estimate the patient age when the first MM driver event was
acquired, we leveraged the high prevalence of chromosomal gains
in MM and their involvement in cancer initiation. Twenty-eight
patients (54%) had at least one multi-gain event, and in six of
these patients, there was evidence of gains acquired in two
distinct time windows (Fig. 7, “Methods,” and Supplementary
Data 9)2,15. Using the patient-specific SBS5 mutation rate, we
estimated the patient age when these events occurred, similar to
what was done for the MRCA. Intriguingly, the first chromoso-
mal duplication was acquired on average 37.5 years (range 8–66)
before sample collection. In 21/27 (78%) cases, the first multi-gain
event occurred before 30 years of age and in 12/27 (44%)
before 20 years (Fig. 7b and Supplementary Data 9). Overall,
the second multi-gain event tended to occur closer to the first
sample collection (median 8, range 0–37), reflecting a protracted
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evolutionary process where drivers accumulate and undergo
selection over time. Finally, we tested the robustness of our
absolute timing estimates to uncertainty in mutational signature
fitting (“Methods”). This confirmed our conclusion that the first
multi-gain event occurs before 30 years of age in the majority of
patients (Supplementary Data 9, Supplementary Fig. 14).
Discussion
In this study, we drew on large WGS and whole-exome sequen-
cing datasets to reconstruct the timeline of mutational processes
shaping the MM genome, providing new insights into its origin
and evolutionary trajectories.
We identified a mutational signature related to melphalan
exposure in relapsed MM, indicating a mutagenic effect of this
agent in clonal plasma cells. This is important given that high-
dose melphalan is considered to be part of the standard first-line
treatment in eligible patients41. Interestingly, not all patients
exposed to melphalan showed evidence of SBS-MM1. We pro-
pose two potential explanations for this observation. First,
according to the recently proposed single-cell expansion model,
cells acquiring melphalan-induced mutations must undergo clo-
nal expansion for those mutations to be detectable by bulk
WGS42. Conversely, in a setting of neutral evolution25, where no
single cell has a major growth advantage, newly acquired muta-
tions would not reach the threshold for detection by WGS
(Fig. 8a). Second, post-melphalan relapse may arise from tumor
cells contaminating the autologous stem cell graft43. Autologous
stem cells are collected before high-dose melphalan therapy and
re-infused after and thus will not have been exposed to melphalan
(Fig. 8a). Future studies will reveal whether mutations induced by
melphalan shape the evolution of relapsed disease or development
of secondary malignancies, such as acute myeloid leukemia44.
Mutational processes related to AID and APOBEC activity
displayed at least four distinct temporal patterns during MM
pathogenesis. Interestingly, our data indicate that AID activity is
not limited to the first GC reaction but persists in at least a subset
of patients, potentially affecting disease evolution. This suggests
that pre-malignant MM cells behave similar to memory B cells,
capable of re-entering the GC to undergo clonal expansion dec-
ades before MM diagnosis (Fig. 8b)45,46. Indeed, the notion of a
prolonged antigen-responsive phase in MM is supported by
studies of lipid-reactive gammopathies, where antigen stimulation
resulted in clonal plasma cell expansion and M spike increase in
mice47,48.
Based on patient-specific estimates of SBS5 mutation rate and
inferred molecular time, we estimated that the first chromosomal
duplication in MM patients was usually acquired before 30 years
of age. Despite uncertainty in our estimates, similar to previous
reports4,6–8,38, we observed a clear pattern across patients sug-
gesting early acquisition of gains. Furthermore, our findings are
in line with epidemiological data. Large population-based studies
have shown that MGUS starts to become detectable at 30 years of
age, after which the prevalence continues to increase49,50. Further
narrowing the window between initiation and a clinically
detectable entity, emerging studies using highly sensitive mass
spectrometry assays have identified monoclonal proteins in serum
up to 10 years before becoming detectable by conventional
methods51.
Our analysis provides a glimpse into the early stages of mye-
lomagenesis, where acquisition of the first key drivers precedes
cancer diagnosis by decades. Defining the time window when
transformation occurs opens up for new avenues of research: to
identify causal mechanisms of disease initiation and evolution, to
better define the optimal time to start therapy, and ultimately
develop early prevention strategies.
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Methods
Subject details. The study involved the use of human samples, which were col-
lected after written informed consent was obtained (WTSI protocol number 15/
046)15. Samples and data were obtained and managed in accordance with the
Declaration of Helsinki. DNA was extracted from CD138+ cells purified from the
bone marrows of 30 patients. Twenty-six (86%) patients had more than one sample
collected at different time points for a total of 67 tumor samples and 30 matched
normals collected from peripheral blood mononuclear cells (Supplementary
Table 1). Samples were collected at different clinical time points: SMM (n= 11),
newly diagnosed MM (n= 15), and relapsed MM (n= 41) (Supplementary
Table 1).
Whole-genome sequencing. Short insert 500-bp genomic libraries were con-
structed, flowcells were prepared, and sequencing clusters were generated
according to Illumina protocols. We performed 108 base/100 base (genomic)
paired-end sequencing on HiSeq X10 genome analyzers. The average sequence
coverage was 38.7-fold. Short insert paired-end reads were aligned to the reference
human genome (GRCh37) using Burrows–Wheeler Aligner, BWA (v0.5.9).
Sequencing data have been deposited in the European Genome phenome Archive
(EGA) under accession number EGAD00001001898.
To this cohort, we added 22 MM patients with available WGS data (dbGap:
phs000348.v2.p1). Raw data was downloaded and processed similar to the in-house
samples.
Whole-genome analysis pipeline. All 89 MM samples from the 2 cohorts were
uniformly analyzed at the Wellcome Sanger Institute15. Briefly, deduplicated
aligned BAM files were analyzed using the following published tools: (1) ASCAT
and Battenberg for clonal and subclonal copy number variants; (2) BRASS for SVs;
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(3) Caveman for single-nucleotide variants (SNVs); (4) Pindel for small
insertions–deletions; and (5) the Dirichlet process to determine the tumor clonal
architecture. Phylogenetic tree reconstruction was performed applying the
pigeonhole principle to mutational clusters defined by the Dirichlet process15. The
MRCA was defined as the cluster of mutations detected as clonal in all samplers
(i.e., trunk of the phylogenetic tree).
Kataegis, or foci of localized hypermutation, was defined as ≥6 consecutive
mutations with an average inter-mutation distance of ≤1 Kb.
Whole-exome sequencing and analysis. Two cohorts of exome data were
included in this study. One comprised of 933 MM patients enrolled within the
CoMMpass trial (NCT01454297; phs000748.v1.p1). The CoMMpass data were
generated as part of the Multiple Myeloma Research Foundation Personalized
Medicine Initiative (https://research.themmrf.org). PhyloWGS52 was used to
reconstruct the phylogenetic tree structure from whole-exome sequencing of 788
patients with available copy number data from low coverage long-insert WGS
(median 4–8×). Seventy-two patients had a sample collected both at baseline and at
first relapse where whole exome sequencing was performed; 24 of these patients
also had available low-coverage long-insert WGS data (Supplementary Data 7). For
the latter 24 patients, mutations were divided into (i) mutations that were clonal in
both samples (trunk of the phylogenetic tree); (ii) mutations that were either
positively or negatively selected at relapse; and (iii) subclonal mutations that did
not show any difference in cancer cell fraction from diagnosis to relapse (neutral).
The second cohort was comprised by 40 MM patients refractory to both
immunomodulatory agents and proteasome inhibitors (INT 15/14;
EGAS00001003709)20,21. Tumor (CD138+ bone marrow plasma cells) and
matched germline samples (DNA from buccal swabs) were processed from 40
patients (80 total samples). DNA was enriched for the coding fraction of the
genome using the SureSelect All Exon V6 Kit (Agilent Technologies) and the
NextSeq500 machine (Illumina) was used to sequence an average of 15.63 Gb per
patient on a 75-bp paired-end protocol. Samples were sequenced to an average
depth of 97×. Paired-end reads were aligned to the reference human genome
(GRCh37) using Burrows–Wheeler Aligner, BWAmem (v0.7.12) and post-
processed following GATK best practices 3.7. Similarly to the CoMMpass work
flow, somatic SNVs were called with three different variant callers: MuTect253,
CaVEMan54, and MuSE55. Small insertions–deletions was called with MuTect2. To
create the confident variant list, we chose the variants called by at least two
algorithms.
Single-cell RNA sequencing. A recently published cohort of single-cell RNA
sequencing from 29 plasma cell dyscrasia patients and 11 controls was interrogated
for AID expression in single cells (GSE117156)36.
VDJ and HCDR3 reconstruction from WGS data. VDJ gene segment usage and
HCDR3 sequences were reconstructed from short reads data using custom scripts
(Supplementary Methods).
Molecular time. The relative timing of each multi-gain event was estimated using
the recently published R package mol_time (https://github.com/nicos-
angelopoulos/mol_time)15. Briefly, we selected all chromosomal duplications with
>50 clonal mutations estimated by the Dirichlet Process (DP). These mutations
were divided using a mixed model (mclust R function) in duplicated (i.e., present
on more than one allele) and non-duplicated (i.e., present on one single allele).
Next, we used the corrected ratio between duplicated and non-duplicated to esti-
mate the relative time of each large chromosomal gain acquisition (i.e., molecular
time). The relative confidence interval for each molecular time was estimated using
a bootstrapping function. To define the time windows in which different gains were
acquired, we performed a multiple hierarchical clustering for each bootstrap
solution (hclust R function) and integrated the most likely results with the Bat-
tenberg CNA changes over the time.
The presence of two duplicated copies of the same allele (tetraploidy) can be
explained by two gains occurring in close temporal succession or in two distinct
time windows. These situations can be differentiated based on the presence or
absence of a distinct intermediary stage, with mutations present on two out of three
alleles (intermediate variant allele fraction 50%). The presence of an intermediary
stage indicates that sufficient time has passed between the two gains to acquire a
distinguishable cluster of mutations. Conversely, the absence of an intermediary
stage indicates that both gains occurred within the same time window.
Mutational signature analysis. The mutational signature analysis was performed
for SBS following three steps as recently described18: (1) mutational signature de
novo extraction; (2) assignment, and (3) fitting. In the first step, we ran both the
hierarchical Dirichlet process (hdp: https://github.com/nicolaroberts/hdp) and
SigProfiler9 workflow to extract the involved known and potentially unknown SBS
mutational signatures. hdp was run with four independent posterior sampling
chains followed by 20,000 burn-in iterations, and the collection of 200 posterior
samples off each chain with 200 iterations between each. SigProfiler was run with
1000 total iteration. To further validate the definition of which mtational signatures
are involved in MM and the robustness of the extracted mutational process, we
analyzed the five-nucleotide context using both approaches.
The second step consisted in the assignment of each extracted process to one
specific mutational signature for SBS included in the recently updated COSMIC
catalogs (https://cancer.sanger.ac.uk/cosmic/signatures/SBS/)9. The mutational
signature assignment approach was comprised of two steps18. In the first, all
mutational signatures extracted by hdp and SigProfiler were assigned to one or a
combination of two COSMIC signatures9. To do so, cosine similarities between the
extracted mutational signatures and each COSMIC signature, or a linear
combination of two COSMIC signatures (using non-negative least squares R
package NNLS), were computed. In the second, we determined whether the
exclusion of each extracted mutational signature would affect the reconstruction
error, i.e., the difference between the original catalogs and the fitted linear
combination of mutational signatures for each sample.
In the final step, we created a fitting algorithm that fits the entire mutational
catalog of each patient with the mutational signatures selected through the first two
steps. In this process, we reconstructed the 96-mutational profile for each sample
excluding one mutational signature after another. The least contributing
mutational signature was sequentially censored for that sample if removal reduced
the cosine similarity <0.01. As a reference for SBS-MM1, we used the 96-class
profile from hdp de novo extraction. Although the profiles extracted by SigProfiler
and hdp were highly similar, the profile from hdp had a lower background
contribution. Thus using the hdp-defined profile increases the specificity of SBS-
MM1 calling by avoiding bleeding from other mutational signatures. SBS1 and
SBS5 were always included, considering that they have been reported to be active in
all normal and tumor tissue types. In this way, we reduced the bleeding of
mutational signatures between samples and quantified the contribution of each
mutational process using the most recent reference9. Importantly, because each
sample is analyzed individually, the results will be reproducible irrespective of other
samples included in the cohort. CIs were generated by drawing 1000 mutational
profiles from the multinomial distribution, each time repeating the
mutational signature fitting procedure, and finally taking the 2.5th and 97.5th
percentile for each mutational signature. Mutational signature transcriptional
strand bias analysis was performed by applying the Poisson test function in R,
incorporated into mmsig. The source code of mmsig is available on GitHub: https://
github.com/evenrus/mmsig.
All three steps for mutational signature analysis (de novo extraction,
assignment, and fitting) were applied to recently published data from human
pluripotent stem cell lines exposed to melphalan and to 15 controls22.
To describe the timeline of each mutational signature, we ran mmsig on
different groups of mutations acquired within different time windows. First, we
analyzed clonal vs. subclonal mutations defined by DP. Thereafter, we focused on
the clonal mutations only; separating them in duplicated vs. non-duplicated using
the molecular time function. For the first analysis only, patients with more than
one sample were considered. Overall, only clusters with >50 mutations were
considered.
We interrogated the mutational signature landscape and the SBS5 contribution
of 89 CLL and 107 B cell lymphoma genomes included in the ICGC/PCAWG
consortium (EGAS00001001692)56. To quantify the contribution of each involved
mutational signature, we ran mmsig including only mutational processes active in
these cancers9. In lymphomas, the correlation between age and SBS5 was
completely lost among patients with >10,000 mutations8.
To divide CoMMpass data in high and low APOBEC, we used the 4th quartile
of APOBEC mutational burden among patients with evidence of APOBEC activity
(49 mutations)26.
Estimating patient age when landmark events occurred. To demonstrate the
existence of a clock-like mutational process in MM, we explored the association
between SBS5/SBS1 and patient’s age by a linear regression model (lm R function)
across a large cohort of newly patients with available whole-exome sequencing data
(CoMMpass; NCT01454297) and across WGS data from B cell lymphoproliferative
disorders (i.e., CLL, MM, and B cell non-Hodgkin lymphoma). Next, following a
recently published statistical workflow4,5,38,39, we used an LME model (lmer R
function) to estimate the mutation rate per year using CoMMpass samples col-
lected at different time points for 72 patients. The same statistical approach was
used on our WGS cohort. Here we considered each evolutionary trajectory inde-
pendently based on phylogenetic tree reconstruction. This is important to avoid
overestimating the mutation rate by pooling together clones that have accumulated
mutations in parallel. Next, we estimated the mutation rate per year for each
patient using LME models to time the MRCA and different multi-gain time
windows. Two tumors in our patients had >10,000 SNVs (MRC006BBM and
V0D57H) and were excluded from this analysis. An additional sample (PD26414)
was excluded considering its ploidy >4 due to two independent whole-genome
duplications15. For the MRCA, we used the fraction of clonal and shared SBS5
variant for each patient with multiple samples collected at different time points
(n= 25). For the timing of different multi-gain events, we calculated the SBS-based
molecular time of the first (and second) multi-gain events. To transform the
relative timing of multi-gain events to absolute time, we repeated the molecular
time workflow using only SBS5 mutational burden pre- and post-gain. To improve
the accuracy of timing estimates, we collapsed together all trisomies acquired in the
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same time window into a single multi-gain event and included only such events
involving >100 SBS5 mutations.
To test the sensitivity of our approach to the assumption that SBS5 is constant
over time, we included a quadratic term for age, effectively allowing for the
mutation rate to parabolically increase with age.
To investigate the impact of uncertainty in mutational signature deconvolution,
we included in the lmer and time estimation both the 2.5% and 97.5% CI of each
SBS5 estimate generated by mmsig.
The full analytical process written in R is provided in Supplementary Data 6, 8,
and 9.
The topography of mutational signatures in MM. Mutational catalogs from all
patients with WGS were combined and divided into 1-Mb bins across the genome.
For each bin, mmsig was applied for mutational signature fitting as described
above. Pearson correlation was applied to assess the pairwise relationships between
the mutation counts for each mutational signature and normalized genomic fea-
tures across all bins. Chromatin accessibility (GM12878), replication time
(GM06990), and fragile sites data were obtained from ENCODE; ALU elements
from repeatmasker; and primary myeloma H3K27ac data as previously
published57.
Data analysis and statistics. Data analysis was carried out in R version 3.6.1.
Standard statistical tests are mentioned consecutively in the manuscript while more
complex analyses are described above. All reported p values are two sided, with a
significance threshold of <0.05.
Data availability
Sequence files are available at the European Genome-phenome archive under the
accession codes: EGAD00001003309 WGS data from 30 multiple myeloma patients;
phs000348.v2.p1 WGS data from 22 multiple myeloma patients; EGAS00001001692:
WGS data from 89 chronic lymphocytic leukemia and 107 B cell lymphomas; phs000748.
v1.p1: WXS and bulk RNA sequencing data from 933 and 792 multiple myeloma
patients, respectively (CoMMpass trial); EGAS00001003709 WXS data from 40 patients
with relapsed/refractory multiple myeloma; GSE117156: single-cell RNA sequencing data
from 29 newly diagnosed patients and 11 control donors.
Received: 10 October 2019; Accepted: 26 March 2020;
References
1. McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution:
past, present. Future Cell 168, 613–628 (2017).
2. Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578,
122–128 (2020).
3. Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. Nat. Rev. Genet.
13, 795–806 (2012).
4. Lee, J. J. et al. Tracing oncogene rearrangements in the mutational history of
lung adenocarcinoma. Cell 177, 1842.e21–1857.e21 (2019).
5. Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell
renal cell cancer: TRACERx renal. Cell 173, 611.e17–623.e17 (2018).
6. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic
cells. Nat. Genet. 47, 1402–1407 (2015).
7. Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem
cells during life. Nature 538, 260–264 (2016).
8. Korber, V. et al. Evolutionary trajectories of IDH(WT) glioblastomas reveal a
common path of early tumorigenesis instigated years ahead of initial
diagnosis. Cancer Cell 35, 692.e12–704.e12 (2019).
9. Alexandrov, L. B. et al. The repertoire of mutational signatures in human
cancer. Nature 578, 94–101 (2020).
10. Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma.
Blood 125, 3069–3075 (2015).
11. Landgren, O. et al. Association of immune marker changes with progression
of monoclonal gammopathy of undetermined significance to multiple
myeloma. JAMA Oncol. 5, 1293–1301 (2019).
12. Maura, F. et al. Moving from cancer burden to cancer genomics for
smoldering myeloma: a review. JAMA Oncol. https://doi.org/10.1001/
jamaoncol.2019.4659 (2019).
13. Manier, S. et al. Genomic complexity of multiple myeloma and its clinical
implications. Nat. Rev. Clin. Oncol. 14, 100–113 (2017).
14. Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of
multiple myeloma. Nat. Rev. Cancer 12, 335–348 (2012).
15. Maura, F. et al. Genomic landscape and chronological reconstruction of driver
events in multiple myeloma. Nat. Commun. 10, 3835 (2019).
16. Fittall, M. W. & Van Loo, P. Translating insights into tumor evolution to
clinical practice: promises and challenges. Genome Med. 11, 20 (2019).
17. Bolli, N. et al. Genomic patterns of progression in smoldering multiple
myeloma. Nat. Commun. 9, 3363 (2018).
18. Maura, F. et al. A practical guide for mutational signature analysis in
hematological malignancies. Nat. Commun. 10, 2969 (2019).
19. Weinhold, N. et al. Clonal selection and double-hit events involving tumor
suppressor genes underlie relapse in myeloma. Blood 128, 1735–1744 (2016).
20. Kumar, S. et al. International Myeloma Working Group consensus criteria for
response and minimal residual disease assessment in multiple myeloma.
Lancet Oncol. 17, e328–346 (2016).
21. Ziccheddu, B. et al. Integrative analysis of the genomic and transcriptomic
landscape of double-refractory multiple myeloma. Blood Adv. 4, 830–844
(2020).
22. Kucab, J. E. et al. A compendium of mutational signatures of environmental
agents. Cell 177, 821.e16–836.e16 (2019).
23. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for
new cancer-associated genes. Nature 499, 214–218 (2013).
24. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer.
Nature 500, 415–421 (2013).
25. Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in
multiple myeloma. Nat. Commun. 5, 2997 (2014).
26. Maura, F. et al. Biological and prognostic impact of APOBEC-induced
mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell
lines. Leukemia https://doi.org/10.1038/leu.2017.345 (2017).
27. Walker, B. A. et al. APOBEC family mutational signatures are associated with
poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997
(2015).
28. Hoang, P. H. et al. Whole-genome sequencing of multiple myeloma reveals
oncogenic pathways are targeted somatically through multiple mechanisms.
Leukemia https://doi.org/10.1038/s41375-018-0103-3 (2018).
29. Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable
from the signature of background mutagenesis by APOBEC3B in human
cancers. Nat. Genet. 47, 1067–1072 (2015).
30. Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine
deaminase signatures during indolent chronic lymphocytic leukaemia
evolution. Nat. Commun. 6, 8866 (2015).
31. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic
leukaemia. Nature 526, 519–524 (2015).
32. Mesin, L., Ersching, J. & Victora, G. D. Germinal center B cell dynamics.
Immunity 45, 471–482 (2016).
33. Puig, N. et al. The predominant myeloma clone at diagnosis, CDR3 defined, is
constantly detectable across all stages of disease evolution. Leukemia 29,
1435–1437 (2015).
34. Rustad, E. H. et al. Stability and uniqueness of clonal immunoglobulin
CDR3 sequences for MRD tracking in multiple myeloma. Am. J. Hematol. 94,
1364–1373 (2019).
35. Pasqualucci, L. et al. Expression of the AID protein in normal and neoplastic B
cells. Blood 104, 3318–3325 (2004).
36. Ledergor, G. et al. Single cell dissection of plasma cell heterogeneity in
symptomatic and asymptomatic myeloma. Nat. Med. 24, 1867–1876 (2018).
37. Maura, F. et al. Role of AID in the temporal pattern of acquisition of driver
mutations in multiple myeloma. Leukemia https://doi.org/10.1038/s41375-
019-0689-0 (2019).
38. Lee-Six, H. et al. The landscape of somatic mutation in normal colorectal
epithelial cells. Nature 574, 532–537 (2019).
39. Moore, L. et al. The mutational landscape of normal human endometrial
epithelium. Preprint at https://doi.org/10.1101/505685 (Nature, 2018).
40. Rasche, L. et al. Spatial genomic heterogeneity in multiple myeloma revealed
by multi-region sequencing. Nat. Commun. 8, 268 (2017).
41. Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with
transplantation for myeloma. N. Engl. J. Med. 376, 1311–1320 (2017).
42. Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51,
1732–1740 (2019).
43. Wuillème, S. et al. Assessment of tumoral plasma cells in apheresis products
for autologous stem cell transplantation in multiple myeloma. Bone Marrow
Transplant. 51, 1143–1145 (2016).
44. Radivoyevitch, T. et al. Risk of acute myeloid leukemia and myelodysplastic
syndrome after autotransplants for lymphomas and plasma cell myeloma.
Leuk. Res. 74, 130–136 (2018).
45. Cowan, G. et al. Massive parallel IGHV gene sequencing reveals a germinal
center pathway in origins of human multiple myeloma. Oncotarget 6,
13229–13240 (2015).
46. Sungalee, S. et al. Germinal center reentries of BCL2-overexpressing B
cells drive follicular lymphoma progression. J. Clin. Invest. 124, 5337–5351
(2014).
47. Nair, S. et al. Clonal immunoglobulin against lysolipids in the origin of
myeloma. N. Engl. J. Med. 374, 555–561 (2016).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15740-9 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1917 | https://doi.org/10.1038/s41467-020-15740-9 |www.nature.com/naturecommunications 13
48. Nair, S. et al. Antigen-mediated regulation in monoclonal gammopathies and
myeloma. JCI insight https://doi.org/10.1172/jci.insight.98259 (2018).
49. Landgren, O. et al. Monoclonal gammopathy of undetermined significance
(MGUS) consistently precedes multiple myeloma: a prospective study. Blood
113, 5412–5417 (2009).
50. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria
for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014).
51. Murray, D. et al. in International Myeloma Workshop. https://www.ncbi.nlm.
nih.gov/pubmed/31836698 (2019).
52. Deshwar, A. G. et al. PhyloWGS: reconstructing subclonal composition and
evolution from whole-genome sequencing of tumors. Genome Biol. 16, 35
(2015).
53. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure
and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
54. Jones, D. et al. cgpCaVEManWrapper: simple execution of CaVEMan in order
to detect somatic single nucleotide variants in NGS data. Curr. Protoc.
Bioinformatics 56, 15.10.11–15.10.18 (2016).
55. Fan, Y. et al. MuSE: accounting for tumor heterogeneity using a sample-
specific error model improves sensitivity and specificity in mutation calling
from sequencing data. Genome Biol. 17, 178 (2016).
56. Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578,
82–93 (2020).
57. Jin, Y. et al. Active enhancer and chromatin accessibility landscapes chart the
regulatory network of primary multiple myeloma. Blood 10, 2138–2150 (2018).
Acknowledgements
This work is supported by the Memorial Sloan Kettering Cancer Center NCI Core Grant
(P30 CA008748), the Instituto de Salud Carlos III (project PMP15/00007, to F.N., E.C.),
the “la Caixa” Foundation Grant No. HR17-00221 (Health Research 2017 Program, to
F.N., E.C.), the Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R
(to E.C.) from Plan Nacional de I+D+I, Generalitat de Catalunya Suport Grups de
Recerca AGAUR 2017-SGR-1142 (to E.C.), the European Regional Development Fund
“Una manera de hacer Europa,” Department of Veterans Affairs Merit Review Award
I01BX001584-01 (to N.M.), and NIH grants P01-155258 (to H.A.-L., P.J.C., K.C.A.,
N.M.) and 5P50CA100707-13 (to N.M., H.A.-L., K.C.A.). F.M. is supported by the
International Myeloma Society (IMS), American Society of Hematology, the Interna-
tional Myeloma Foundation, and The Society of Memorial Sloan Kettering Cancer
Center. N.B. is funded by the University of Milan (project 22597 - PSR2017_DIP_032)
and by the European Research Council under the European Union’s Horizon 2020
research and innovation programme (grant agreement no. 817997). X.S.P. is supported
by the Ministerio de Economía y Competitividad Grant No. SAF2017-87811-R. F.N. is
supported by a pre-doctoral fellowship of the MINECO (BES-2016-076372). E.C. is
supported by ICREA under the ICREA Academia programme. The work of R.S. in the
framework of the ICGC MMML-Seq and derived mutational signatures has been funded
by BMBF (FKZ 01KU1002A, 01KU1505 and 031A428H).
Author contributions
F.M. designed the study, collected and analyzed data, and wrote the paper; E.R. and V.Y.
collected and analyzed data and wrote the paper; D.L. and P.J.C. collected and analyzed
data; N.B. analyzed data and wrote the paper; F.N., N.A., K.J.D., T.J.M., R.O., B.Z., and
G.L. analyzed data; C.C., V.M., P.C., P.M., K.C.A., E.P., L.A., X.S.P., E.C., R.S., H.A.L.,
O.L., and N.M. collected data.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-15740-9.
Correspondence and requests for materials should be addressed to F.M.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15740-9
14 NATURE COMMUNICATIONS |         (2020) 11:1917 | https://doi.org/10.1038/s41467-020-15740-9 | www.nature.com/naturecommunications
